Pharmafile Logo

Maximising patient adherence by leveraging the patient/ physician/ pharma relationship

Director Marc Yates looks at the problem of patient compliance – can a better understanding of patient attitudes, needs and behaviours help pharma develop strategies to improve adherence?

Consider the scenario – the physician has been detailed, is sold on your brand’s benefits and prescribes it to the patient. Unfortunately the patient, perhaps unconvinced of what the drug will do for them, either doesn’t fill the prescription or fails to adhere properly to the treatment regime – that’s assuming they even present in the first place. It’s a common problem, especially for chronic diseases like diabetes, hypertension and osteoporosis, and one the pharmaceutical industry has invested much time and money trying to solve. Some companies have responded by developing sophisticated technological solutions, such as wireless devices, that remind patients when to take their medication. Unfortunately these solutions have not raised adherence levels because they have failed to get to the heart of the matter. To develop an effective adherence strategy, you first need to develop a more in-depth understanding of the attitudes and behaviours of both the patient and the physician, and the relationship which exists between them.

Download and read the complimentary whitepaper at http://bit.ly/1R0gWjr

We are one of the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical industry, we use our expertise and experience to deliver intelligent, tailor-made solutions. We provide strategic recommendations that go beyond research, helping our clients to answer their fundamental business challenges.
 

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

Review of Disease Promotion Campaign using Facial Analysis

Our client had developed a visual and emotion-invoking, online disease awareness campaign aimed at challenging physicians’ current perceptions of treatment. Research was required to understand physicians’ reactions to the campaign...

Emotional Recognition using Facial Analysis

Do you have a poker face or does your expression give you away?  According to psychologists, a lot of emotional information can be drawn from our facial expressions, which is...

Living with NASH: An Unexpected Diagnosis

Published in eyeforpharma November 2017 by Mariel Metcalfe

20 questions: Round 7

As it's our 20th year anniversary, we invited our employees to play our version of 20 questions - this month "What project or event has been most memorable to you at RP?"Watch...

Innovation, sustainability and prosperity: Japan’s healthcare vision for the future

The vision for Japan 2035; A healthcare system that delivers unrivalled health outcomes, providing secure and responsive care for all members of society, sustainable, and contributing to prosperity in the...

Tools to action your segmentation

Our tools for ensuring a successful segmentation rollout

Research Partnership launches new patient Living with Atopic Dermatitis (US) 2017 report

Living with Atopic Dermatitis (AD) is a study conducted amongst 100 adults and 50 caregivers  in the US. The report will consist of 45-minute quantitative and 30-minute qualitative interviews with AD...

The value of design thinking: Incorporating creative and graphic design into pharma market research

How do we keep research design fresh and interesting? How do we ensure that we’re inspiring our respondents to give us enlightening new insights, and encourage new ways of thinking?There...

Research Partnership launches new patient Living with Psoriasis 2017 (EU) report

Living with Psoriasis is a study conducted amongst 615 patients in Europe. The report will consist of 30-minute online interviews with 600 patients and 15 qualitative interviews. It can be purchased...

Deep Dive – MINT: opportunities in ‘frontier’ markets?

According to British economist Jim O’Neill, MINT is the new BRIC. What is MINT? An acronym he coined for the ‘frontier’ markets of Mexico, Indonesia, Nigeria and Turkey. These are...